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Chloroquine Promotes Apoptosis in Melanoma
Cells by Inhibiting BH3 Domain–Mediated PUMA
Degradation
Alexander J. Lakhter1, Ravi P. Sahu1, Yang Sun2, William K. Kaufmann3, Elliot J. Androphy1,
Jeffrey B. Travers1,4 and Samisubbu R. Naidu1
The Bcl homology-3 (BH3)-only protein p53 upregulated modulator of apoptosis (PUMA) counters Bcl-2 family
anti-apoptotic proteins and promotes apoptosis. Although PUMA is a key regulator of apoptosis, the post-
transcriptional mechanisms that control PUMA protein stability are not understood. We show that a lysosome-
independent activity of chloroquine (CQ) prevents degradation of PUMA protein, promotes apoptosis, and
reduces the growth of melanoma xenografts in mice. Compared with wild-type PUMA, a BH3 domain–deleted
PUMA protein showed impaired decay in melanoma cells. Fusion of the BH3 domain to a heterologous protein
led to its rapid turnover that was inhibited by CQ. Although both CQ and inhibitors of lysosomal proteases
stalled autophagy, only CQ stabilized PUMA protein and promoted apoptosis. Our results reveal a lysosomal
protease-independent activity of CQ that selectively promotes apoptosis in melanoma cells.
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INTRODUCTION
Melanoma is one of the most aggressive cancers that presents
a great clinical challenge to treat. Although primary mela-
noma is curable by early surgical excision, metastatic mela-
nomas are highly aggressive with an average survival of 6–10
months (Tsao et al., 2012). Despite a large number of clinical
trials and considerable progress in understanding the
molecular etiology, metastatic melanoma remains resistant
to treatment and the lifetime risk of it continues to steadily
increase (Gray-Schopfer et al., 2007). Recently, BRAF and
mitogen-activated protein kinase inhibitors have shown
significant clinical activity, yet these successes are limited by
the swift development of resistance (Ji et al., 2012). Identifi-
cation of novel therapeutic targets and additional treatment
options are much needed to combat this malignancy.
Apoptosis is a cellular demolition process that involves an
intricate interplay of pro- and anti-apoptotic Bcl-2 family
proteins, leading to mitochondrial damage and cytochrome
C release followed by caspase activation (Green and Evan,
2002; Chipuk et al., 2010). Resistance to apoptosis has a
central role in tumor progression and enables malignant cells
to become unresponsive to chemotherapy and radiation
treatment modalities (Green and Evan, 2002). Increased
production of anti-apoptotic proteins or silencing of pro-
apoptotic proteins contribute to impaired apoptosis. Bcl-2
family anti-apoptotic members consist of Bcl-2, Bcl-Xl, Mcl-1,
and Bcl-w, and pro-apoptotic members include Bim, Bid, Bad,
Bak, Bax, NOXA, and p53 upregulated modulator of apoptosis
(PUMA; Chipuk et al., 2008; Chipuk and Green, 2008; Chipuk
et al., 2010). The pro-apoptotic proteins harbor a single Bcl
homology-3 (BH3) domain and are called as BH3-only
proteins. The BH3 domain of these proteins contains an
amphipathic a-helix structure that engages the hydrophobic
groove of pro-survival partners to activate Bak and Bax at the
mitochondria (Sattler et al., 1997).
The levels of BH3-only proteins are tightly regulated to
restrict cell destruction (Strasser et al., 2011). Expression of
these proteins is regulated by various mechanisms including
enhanced transcription and post-translations modifications
(Puthalakath and Strasser, 2002). The best example of
transcriptional control of BH3-only proteins are derived from
studies of p53-mediated transcriptional targets. In response to
DNA damage, p53 binds to specific sequence elements near
the promoters of PUMA and NOXA genes, and enhances their
transcription (Nakano and Vousden, 2001; Yu et al., 2001). As
a result, pro-apoptotic BH3-only protein levels increase and
result in mitochondrial permeabilization with subsequent
activation of caspase-mediated apoptosis. Tumor cells avoid
this cell death mechanism by inactivating upstream
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components of p53 or selecting for p53 mutations (Vousden
and Lane, 2007; Vousden and Prives, 2009). Although
mutations in p53 gene are common in multiple
malignancies, they are rare in melanoma (Chin et al., 1998;
Lee and Herlyn, 2012). The upstream regulator of p53 called
p14ARF is mutated in familial melanoma (Chin et al., 1998).
Perturbation of downstream components of the apoptotic
pathway provides a selective advantage in circumventing the
need for inactivating mutations of the p53 gene. For example,
expression of the downstream apoptotic factor Apaf-1 is
silenced in some melanomas (Soengas et al., 2001). These
studies support the notion that both upstream and downstream
components of p53 pathways are disabled in melanoma.
Autophagy is a regulated degradative process that recycles
damaged organelles and cytoplasmic macromolecules to
enable cell survival (Levine and Kroemer, 2008). Typically,
autophagy involves sequestration of cytoplasmic components
in a double membrane, the contents of which are degraded by
delivery to the lysosome. Chloroquine (CQ) is a classical anti-
malarial and anti-inflammatory drug that inhibits lysosomal
acidification. In cell culture assays, CQ is commonly used as
an inhibitor of autophagy. Depending on the type of cancer,
autophagy may become dysregulated in a manner that enables
tumor cell survival even in a limited nutrient environment
(Baehrecke, 2005; White, 2012). This implication led to the
use of CQ as a small molecule inhibitor of autophagy in
xenograft tumor studies and clinical trials (Tormo et al., 2009;
Sheen et al., 2011; Yang et al., 2011; Amaravadi et al.,
2011b). Although CQ has also been reported to promote
apoptosis in several tumor models (Boya et al., 2005;
Amaravadi et al., 2007; Maclean et al., 2008; Walls et al.,
2010; Tang et al., 2011), its effects on PUMA remain unclear.
Here we use CQ to reveal the BH3 domain-dependent and
lysosome-independent degradation of PUMA protein and
associated apoptosis in melanoma cells.
RESULTS
Chloroquine activates apoptosis in melanoma cells
As CQ exerts anti-tumor activity (Amaravadi et al., 2007;
Sheen et al., 2011; Amaravadi et al., 2011b), we examined
cell survival of human melanoma-derived cell lines (SK-
MEL23, MEL501, MELSK5, MEL526, and MEL624) and non-
melanoma cell lines (HCT116, MCF7, and H1299) after
treatment with CQ. On the basis of pilot studies with a
range of concentrations, we chose 50mM CQ for further
experiments. Viability of the majority of melanoma cell lines
decreased with 24 hours of exposure to 50mM CQ (Figure 1a).
In contrast, viability of the non-melanoma cell lines was
largely unchanged. We then measured caspase activity as an
indicator of apoptosis. The decreased viability of melanoma
cells correlated with a dramatic increase in caspase levels,
which was not observed in the non-melanoma cell lines
(Figure 1b).
Oncogenic mutations in BRAF and N-RAS are known to
promote melanomagenesis (Davies et al., 2002; Pollock et al.,
2003; Dankort et al., 2009). To explore the relevance of these
upstream signaling pathways in CQ-induced apoptosis, we
used human melanoma cell lines that express wild-type (wt)
BRAF and N-RAS genes (SK-mel187, mel505, RPMI8322),
cells mutant for N-RAS (SK-mel103, mel224, VMM39), and
cell lines with BRAF mutations (SK-mel24, SK-mel28,
WM2664). All melanoma cell lines with the exception of
SK-mel187 showed decreased viability and a corresponding
increase in caspase activity in response to the CQ treatment
(Figure 1c and d). Therefore, there was no correlation between
CQ responsiveness and the oncogenic mutation in these
melanoma cell lines.
CQ inhibits melanoma tumor growth in vivo
To test the effects of CQ in an in vivo model, we implanted
SK-MEL23 melanoma cells in NOD-SCID mice and evaluated
the effects of CQ on subcutaneous tumor growth. Melanoma
cells were allowed to establish an average volume of 100 mm3
at which point the mice were divided into two groups. A set of
four mice served as vehicle control and six mice were treated
with a low dose of CQ (25 mg per kg body weight) on an every
3-day treatment schedule for 21 days. Tumor volume mea-
surements showed that CQ treatment reduced tumor volume
in the experimental group (P¼0.0001) compared with that in
the vehicle controls (Figure 2a). There were no differences in
total body weight between the treatment and control groups.
At the end of the study, xenografts were excised and gross
weight values of tumors were recorded (Figure 2b). Consistent
with tumor volume measurements, we found a statistically
significant (Pp0.05) reduction in tumor mass from this low
dose of CQ-treated animals as compared with that of the
vehicle group.
CQ promotes PUMA protein accumulation in melanoma cells
CQ-induced activation of apoptosis led us to study its effects
on expression of the pro-apoptotic protein PUMA. SK-MEL23
and VMM39 melanoma cells were treated with etoposide as
an activator of p53-mediated PUMA induction (Nakano and
Vousden, 2001; Yu et al., 2001) or with different
concentrations of CQ (25 and 50mM). Immunoblot analysis
of these cell extracts showed that etoposide induction of p53
increased the levels of its target proteins PUMA and p21
(Figure 3a and b). Remarkably, CQ also increased levels of
PUMA protein in a dosage-dependent manner, whereas the
levels of p53 and p21 did not change. In an effort to address
the requirement for PUMA in CQ-mediated apoptosis, SK-
MEL23 cells were transfected with control or PUMA small
interfering RNAs and exposed to CQ. The results showed that
small interfering RNA efficiently depleted PUMA protein, and
this resulted in dramatic reduction of CQ-mediated apoptosis
(Supplementary Figure S1 online). To substantiate these
results, we treated additional melanoma cell lines (mel526
and mel501) with CQ and observed similar effects on PUMA
(Supplementary Figure S2 online). Although PUMA protein
was induced in response to p53 activation (Figure 3a and b),
CQ did not change the levels PUMA protein in MCF7 breast
cancer cells (Supplementary Figure S3 online) and, corre-
spondingly, there was no apoptotic response (Figure 1b). To
test whether the observed increase in PUMA protein levels
was due to transcription, we treated several melanoma cell
lines with CQ and quantified PUMA transcripts. The results
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showed that CQ did not change the transcript levels of PUMA
(Figure 3d and e).
To demonstrate that the CQ-mediated increase in the levels
of endogenous PUMA protein is due to inhibition of its
degradation, we determined the stability of PUMA protein in
the presence or absence of CQ. Cycloheximide is a de novo
protein synthesis inhibitor commonly used to evaluate the
half-life of proteins (Ballard, 1977; Waters et al., 1991;
Carreira et al., 2006). SK-MEL23 melanoma cells were
treated with cycloheximide in the presence or absence of
CQ, and the cell extracts were blotted for PUMA protein
(Figure 4a and b). PUMA protein signal intensity from three
independent experiments was quantified by luminescence
measurements (Figure 4c). There was a 50% decrease of
endogenous PUMA protein in 3 hours in the absence of CQ.
CQ prolonged the stability of this protein, and even after
5 hours of cycloheximide exposure nearly 80% of PUMA
protein remained.
BH3 domain is essential for PUMA protein degradation
The BH3 domain of PUMA engages the hydrophobic groove
of anti-apoptotic family members to activate apoptosis. As
this domain is critical for apoptosis, we reasoned that it may
be involved in PUMA destabilization, and that a mechanism
in melanoma cells specifically may target this domain to
avoid cell death. To test this idea, we introduced plasmids
encoding for full-length or BH3-deletion mutant PUMA into
melanoma cells and conducted cycloheximide-chase assays
for these ectopically expressed proteins. After 5 hours of
cycloheximide incubation, nearly 50% of full-length PUMA
protein remained (Figure 5a and b), whereas the BH3 domain
deletion mutant protein levels were unchanged. These results
suggest that the BH3 domain has a critical role in PUMA
protein destabilization. We questioned whether this BH3
domain was sufficient to direct degradation of a heterologous
protein. We constructed green fluorescent protein (GFP)
fusions with a BH3 domain or a mutant BH3 domain devoid
of the conserved amino acid sequence Leu–Arg–Arg
(Figure 5c). We introduced these recombinant plasmids into
melanoma cells and examined GFP expression. No GFP
signal was visualized with the wt BH3 fusion-transfected
cells (Figure 5d). In contrast, the mutant BH3 domain showed
intense GFP fluorescence (Figure 5d). To further determine
the effects of CQ on BH3 fusion protein stability, melanoma
cells were transfected with these GFP constructs and treated
with CQ. Immunoblots for GFP showed that CQ treatment
restored the levels of wt BH3 domain–fused GFP (Figure 5e).
These results reinforce the essential role of the BH3 domain in
PUMA degradation, and that CQ inhibits degradation of
PUMA actuated by this domain.
As CQ did not elicit an apoptotic response and did not
stabilize PUMA protein in non-melanoma cell lines, we ques-
tioned the integrity of this BH3-targeting mechanism in these
cell lines. When GFP fusion constructs were transduced into
non-melanoma cell lines (MCF7, H1299, and HCT116), similar
GFP fluorescence intensities were observed for both wt and
mutant BH3 fusion proteins (Supplementary Figure S4 online).
Lysosomal protease-independent degradation of PUMA protein
CQ is generally considered to exert its drug effect through
inhibition of lysosomal acidification. As melanoma cells
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Figure 1. Chloroquine (CQ) promotes apoptosis in melanoma cell lines. Three non-melanoma and five melanoma cell lines were exposed to 50mM CQ; cell
viability (a) and apoptosis (b) were measured at indicated time points. (c, d) Wild-type for N-RAS and BRAF or its mutant melanoma cell lines were treated with
CQ as in a and b, and the cell viability (c) and apoptotic response (d) to CQ were assessed.
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Figure 2. Chloroquine (CQ) reduces growth of human melanoma cells in
mice. (a) NOD-SCID mice were implanted with SK-MEL23 cells, 21 days post
implantation; mice were divided into two groups for vehicle and CQ treatment.
Tumor volumes of vehicle or CQ-treated mice were measured at indicated
days and the growth kinetics of tumor volume are shown on the graph
(P¼ 0.0001). (b) Dissected tumors from vehicle and CQ-treated mice were
weighed (Pp0.05).
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treated with CQ increased the levels of PUMA protein, we
explored whether a lysosomal process causes PUMA protein
destabilization. Surprisingly, bafilomycin A, a commonly
used lysomotropic compound, and the lysosomal cathepsin
inhibitor ALLN had no affect on PUMA protein levels
(Supplementary Figure S5 online). Furthermore, the protease
inhibitor leupeptin and proteasome inhibitor lactacystin did
not inhibit the degradation of PUMA protein (Supplementary
Figure S5 online). MG132 treatment produced a slight
increase in the PUMA protein levels, but not nearly as much
as CQ (Supplementary Figure S5 online). We reasoned that
this is most likely due to robust p53 protein stabilization by
MG132. Although ALLN, MG132, and lactacystin increase
levels of p53, PUMA protein degradation was specifically
inhibited by CQ. We also incubated melanoma cells with
either CQ or the combination of lysosomal protease inhibitors
E64d and pepstatin A (Tanida et al., 2005). The increase in
PUMA was exclusive to CQ, although both treatments strongly
inhibited lysosomal activity as assessed by the autophagy
markers LC3 and p62 (Figure 6a–d). Consistent with their
effects on PUMA, CQ but not the lysosomal inhibitors
stimulated apoptosis (Figure 6e). These results clearly demon-
strate that lysosomal protease function is dispensable for
PUMA degradation in melanoma cells.
DISCUSSION
Impaired apoptosis is one of the critical steps in malignant
transformation. Understanding this pathway in tumor cells
may have major clinical implications, as chemoresistant
malignancies are generally unable to activate apoptotic
responses. Here we show that CQ has a profound effect on
SKMEL23
PUMA
p53
p21
Actin
PUMA
VMM39
0
Con
t
Eto
p
VMM39
25 μ
M
50 μ
M C
Q
Con
t
Eto
p
25 μ
M
50 μ
M C
Q
50 μ
M C
Q
25 μ
M C
Q
Eto
pos
ideCon
t
50 μ
M C
Q
25 μ
M C
Q
Eto
pos
ideCon
t
0
0.5
R
el
at
iv
e 
fo
ld
R
el
at
iv
e 
fo
ld
1
1.5
0
0.5
1
1.5
2
2.5
50
100
SK-MEL23
150
Ar
bi
tra
ry
 u
ni
ts 200
250
0
50
100
150
Ar
bi
tra
ry
 u
ni
ts 200
250p53
p21
Actin
PUMA transcript (VMM39)PUMA transcript (SK-MEL23)
Co
nt
Eto
po
sid
e
25
 μM
 
CQ
50
 μM
 
CQ
Co
nt
Eto
po
sid
e
25
 μM
 
CQ
50
 μM
 
CQ
Figure 3. Chloroquine (CQ) promotes accumulation of p53 upregulated modulator of apoptosis (PUMA) protein in melanoma cells. (a, b) Indicated
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Figure 4. Chloroquine (CQ) inhibits degradation of p53 upregulated
modulator of apoptosis (PUMA) protein in melanoma cells. (a, b) To
determine the half-life of endogenous PUMA protein, control or CQ-treated
melanoma cells were exposed to cycloheximide, a protein synthesis inhibitor,
and cell extracts collected at different time points were blotted with PUMA
antibody. (c) Protein decay analysis from three experiments is shown.
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melanoma cell viability and promotes apoptosis. Although CQ
did not alter the levels of p53 protein, it caused a transcrip-
tion-independent increase in levels of PUMA protein and
promoted apoptosis. We demonstrate that CQ increases the
half-life of PUMA protein in multiple human melanoma-
derived cell lines. In these cells, the BH3 domain of PUMA
protein is responsible for its destabilization. Remarkably, the
BH3 domain was sufficient to promote degradation of a
heterologous protein, and this was selective for melanoma
cells. Furthermore, we demonstrate that CQ-mediated inhibi-
tion of PUMA protein degradation does not depend on
lysosomal proteases. As the BH3 domain is critical for pro-
apoptotic function for the protein, melanoma cells recognize
this death promoting peptide region and degrade PUMA to
avoid cell death.
Macroautophagy is commonly referred to as autophagy. In
response to nutrient depletion, activation of autophagy leads
to digestion of cytosolic macromolecules that provides energy
sources required for cell survival. Importantly, oncogenic RAS
transformation relies on autophagy to maintain energy balance
(Guo et al., 2011; Lock and Debnath, 2011; Marino et al.,
2011). This represents an advantage for malignant cells to
multiply in a microenvironment with limited nutrient supplies.
Therefore, targeting this autophagy dependency is a rational
approach for anti-tumor therapy (Amaravadi et al., 2011a). For
example, inhibition of autophagy by CQ led to selective
pancreatic tumor regression and prolonged survival of mice
implanted with pancreatic cancer xenografts (Yang et al.,
2011). HeLa cells exposed to the autophagy inhibitors
hydroxychloroquine, bafilomycin A1, and monensin
displayed increased mitochondrial cell death (Boya et al.,
2005). In our study, and consistent with the observations from
other reports (Guo et al., 2011; Yang et al., 2011), CQ
exposure did not elicit caspase-mediated apoptotic responses
in non-melanoma cell lines MCF7, HCT116, and H1299.
Importantly, the majority of the melanoma cells dramatically
activated apoptosis upon treatment with CQ. This led us to
investigate the role of the p53–PUMA pathway that has been
documented to initiate caspase-dependent apoptosis. Surpris-
ingly, CQ treatment of melanoma cells resulted in PUMA
protein accumulation, but there was no increase in p53
protein. It is relevant to note that PUMA transcription is
regulated by p53-dependent and -independent mechanisms
(Schumm et al., 2006; Sykes et al., 2006; Tang et al., 2006;
Wang et al., 2009; Gomes and Espinosa, 2010). Quantitative
transcript analysis of CQ-treated melanoma cells showed that
PUMA transcription was unchanged. Furthermore, protein
stability studies demonstrate that CQ inhibits proteolysis of
PUMA. PUMA protein undergoes phosphorylation at multiple
sites, particularly serine 10, which leads to its destabilization
(Fricker et al., 2010). It is unlikely that CQ impacts this
phosphorylation as we demonstrate CQ stabilization is
dependent on the BH3 domain of PUMA. It is unlikely that
degradation of PUMA protein involves the proteasome for the
following reasons: the absence of lysines for ubiquitin
conjugation in PUMA and CQ promoted PUMA protein
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stability in a lysosomal activity-independent manner. It is
likely that CQ can stabilize other BH3-domain proteins.
However, unlike PUMA that lacks lysine, NOXA contains
multiple lysines that may facilitate ubiquitin-mediated
proteasomal degradation even in the presence of CQ.
CQ is widely used to treat malaria by halting the Plasmo-
dium falciparum replication cycle (Cooper and Magwere,
2008). CQ acts as a weak base that neutralizes low pH in
the lysosome, thereby inactivating lysosomal proteases. We
demonstrate an activity of CQ that is distinct from its classical
function of lysosomal protease inhibition. CQ blocked
degradation of PUMA, which requires the BH3 domain. This
inhibition cannot be mediated by ubiquitination of PUMA nor
dependent on lysosomal proteases, so the mechanism remains
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to be determined. The mechanism may be unique to
melanoma, as we have not observed CQ-associated PUMA
protein stability in several non-melanoma cell lines. Further
investigation on how CQ alters the catabolism of BH3
proteins, such as PUMA, may lead to novel drug targets.
Acidic organelles are generally sensitive to CQ exposure, as it
is a weak base that neutralizes their pH. This property of CQ
led us to suspect melanosomes as a possible site of PUMA
protein degradation. Lysosomal protease inhibitors treatment
increased the levels of the melanosome protein PMEL17 to a
larger extent than CQ exposure (Supplementary Figure S6
online), suggesting that PUMA may not be degraded in
melanosomes.
Given the limited treatment options for melanoma, these
studies suggest that melanoma may respond to a blockade of
the mediators of BH3-dependent PUMA turnover. Consistent
with our findings, CQ reduced melanoma tumor growth
in vivo. Further evidence is suggested by the observation that
leucine deprivation combined with CQ exposure led to
widespread apoptosis in human melanoma cells (Sheen
et al., 2011). High-dose IL-2 is currently a treatment option
for advanced-stage melanoma. However, the toxicity
associated with IL-2 administration has been problematic.
Recently, IL-2 was combined with CQ to demonstrate
inhibition of metastatic tumor growth in a murine model
(Liang et al., 2012). The present studies provide a molecular
basis for the anti-melanoma effect of CQ. Combined with our
demonstration of CQ-associated PUMA activation, we
propose that CQ may be useful in combination therapy for
metastatic melanoma. Moreover, CQ might exert synergistic
effects with chemotherapeutic agents (e.g., temozolomide) or
BRAF inhibitors (Bollag et al., 2012) in the treatment of
melanoma. Although our in vivo studies show moderate
tumor growth inhibition in the presence of 25 mg kg1 of
CQ, the concentration of CQ used in our in vitro experiments
are higher than that used clinically. Additional animal studies
are needed to translate the use of CQ in combination therapy
to man.
MATERIALS AND METHODS
Cell culture and reagents
HCT116 and MCF7 cells were maintained in high-glucose DMEM
medium (Invitrogen, Carlsbad, CA) supplemented with L-glutamine
and sodium pyruvate, with 10% fetal bovine serum (Sigma, St Louis,
MO). H1299 and melanoma cell lines (SK-MEL23, MEL501, MEL526,
MEL624, and MEL-697) were maintained in RPMI media (Invitrogen)
with 10% fetal bovine serum (Sigma). Bafilomycin A, CQ dipho-
sphate, leupeptin, and MG132 were obtained from Sigma; ALLN,
etoposide, and Z-Vad-Fmk from R&D Systems (Minneapolis, MN),
E64d and Pepstatin A (Cayman Chemical, Ann Arbor, MI) and
lactacystin (AG Scientific, San Diego, CA).
Transfection
Human BH3 domain and the BH3-domain mutant lacking the LRR
motif were cloned into enhanced GFP vector, to express GFP fusion
proteins. Cells were grown to 50–60% confluency in six-well culture
plates (Corning, Corning, NY) with collagen-1 coated coverslips (BD
Biosciences, San Jose, CA). All melanoma cell lines were transfected
with FuGENE HD (Promega, Madison, WI) according to manufac-
turer’s protocol. HCT116, MCF7, and H1299 cells were transfected
with Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s protocol.
Whole-cell extracts and western blot analysis
Whole-cell extracts were prepared in urea buffer (6 M urea, 100 mM
sodium dihydrophosphate, 10 mM Tris pH 8). SDS-PAGE was per-
formed using TGX gradient gels (Bio-Rad, Hercules, CA) and
transferred onto polyvinylidene difluoride (Millipore, Bedford, MA)
using TransBlot SD semi-dry transfer apparatus (Bio-Rad) as per the
manufacturer’s guidelines. The blots were probed with following
antibodies: GFP, p53 and p21 (Santa Cruz, Santa Cruz, CA), LC3
(Novus Biologicals, Littleton, CO), NOXA (Pierce, Rockford, IL),
PUMA (AnaSpec, Fremont, CA), and actin and p62 (Sigma). Blot
images were captured on ImageQuant LAS 4000 digital imaging
system (GE Healthcare, Piscataway, NJ).
Apoptosis and viability assays
The cells (10 103/each well) were plated in 96-well plates (Corn-
ing). After culture overnight, either fresh media (control) or fresh
media containing 50mM of CQ was added for indicated time periods.
The activation of apoptosis was determined using Caspase-Glo 3/7
Assay System according to the manufacturer’s instructions (Promega).
Cell viability was assessed using MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)-based
assay (Promega).
In vivo tumor implantation
NOD-SCID mice were implanted with 1.5 million of human
melanoma SK-Mel23 cells in 100ml serum-free media subcutaneously
into the right hind flank. Tumors were allowed to develop for 21 days
until they reached average palpable size of 100 mm3. At this point,
the animals were randomly divided into two groups, four controls and
six treatment subjects. The control group received intraperitoneal
injections of sterile saline (50ml), and the treatment group was
similarly injected with CQ at the concentration of 25 mg kg 1 in
saline, twice a week for 3 weeks. Xenograft size was measured twice
a week with a digital caliper, and the ellipsoidal tumor volumes were
recorded before administration of each placebo or treatment injec-
tion. The Animal Care and Use Committee approved all procedures
used in these experiments.
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